The strong Q2 beat on revenue and Adjusted EBITDA, combined with the elimination of all 2028 Convertible Notes debt, removes a key overhang and strengthens the balance sheet. Traders should watch for the XP-8121 Phase 3 program webinar on September 9, 2026, which could serve as a major pipeline catalyst. The tightened guidance midpoint of $387.5M implies H2 revenue of ~$212M, requiring continued Recorlev momentum.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $7.36entry
- T+1 · 3mo ago +7.74%α +7.13% · $7.93
- T+5 · 3mo ago +13.18%α +11.97% · $8.33
- T+20 · 3mo ago +16.71%α +16.11% · $8.59
- T+60 · 18d ago +45.52%α +47.19% · $10.71
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xeris Biopharma reported Q2 2026 total revenue of $92.1M (+29% YoY) and net product revenue of $91.0M (+34% YoY), driven by Recorlev's 81% growth to $56.8M. The GAAP net loss of $31.1M was largely due to a $31M non-cash charge from convertible note exchange agreements, while Adjusted EBITDA improved to $19.3M. The company tightened full-year 2026 revenue guidance to $385-390M, reflecting confidence in continued commercial momentum, and eliminated all remaining 2028 Convertible Notes debt through cash and stock exchanges, strengthening the balance sheet.
Key Financial Metrics
Key Facts
- Total revenue of $92.1M in Q2 2026, up 29% YoY from $71.5M
- Net product revenue of $91.0M, up 34% YoY, driven by Recorlev (+81% to $56.8M)
- GAAP net loss of $31.1M includes a ~$31M non-cash charge from convertible note exchange agreements
- Adjusted EBITDA improved 54% to $19.3M from $12.5M in Q2 2025
- Full-year 2026 revenue guidance tightened to $385-390M from $380-390M
- All $33.5M of 2028 Convertible Notes eliminated via cash ($23M) and stock (~8.6M shares) exchanges in July 2026
- Cash and cash equivalents increased to $121.7M at June 30, 2026 from $111.0M at Dec 31, 2025
- Total shares outstanding rose to 182.3M at July 31, 2026 from 172.6M at April 30, 2026
Financial Impact
Revenue growth of $20.6M YoY (+29%); debt reduction of $33.5M (all 2028 Convertible Notes eliminated); Adjusted EBITDA improvement of $6.7M YoY
Risk Factors
- Share dilution from ~8.6M new shares issued in July 2026 for debt exchange
- SGA expenses grew 37% YoY, outpacing revenue growth of 29%
- XP-8121 Phase 3 trial initiation later in 2026 carries execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001867096-26-000063 |
| Document: xers-20260806.htm | 0001867096-26-000063 |
| Document: 0001867096-26-000063-index-headers.html | 0001867096-26-000063 |
| Document: 0001867096-26-000063-index.html | 0001867096-26-000063 |
| Document: 0001867096-26-000063.txt | 0001867096-26-000063 |
| 8-K Data (Synthetic) | 0001867096-26-000063 |
Track record
25 reports on XERS
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +31.13% at T+20 after the Sep 9, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $15.86 Now $16.70 +5.30% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $15.20 Now $16.70 +9.87% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago 3 Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $10.35 Now $16.70 +61.35% settles Dec 2
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $10.17 Now $16.70 +64.21% settles Dec 1
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $10.71 Now $16.70 +55.93% settles Nov 30
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $9.77 to $16.52 Now $16.70 +70.93% ▲ +69.09% +70.36% vs SPY
- Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $10.13 to $10.71 Now $16.70 +64.86% ▲ +5.73% +8.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers